New guidelines on bronchiectasis in children are aiming to raise more awareness of key aspects of diagnosis and treatment in younger age groups, after evidence found there are large disparities in standards of care and outcomes.
There are substantial differences between the condition in children and adolescents and when it presents in adults, the recommendations from a European Respiratory Society Task Force point out.
This includes different different lower airway microbial profiles and likely treatment outcomes but also that bronchial dilatation is reversible in children if treated properly at an early stage, the Task Force said.
The guidelines address a current gap of up-to-date international evidence-based recommendations in this group, according to co-author Prof Andrew Bush, a consultant paediatric chest physician at the Royal Brompton and Harefield NHS Foundation Trust, London.
Speaking with the limbic, he pointed out that bronchiectasis in children was very much an orphan speciality, and there was still a lot that wasn’t known about the most effective management. Still, there was more recognition about the importance of early diagnosis.
“There’s no question that if you initiate treatments early and aggressively you can reverse bronchial dilatation.”
He added that when you look back at the medical history of some adults, their symptoms go back into childhood but were never picked up.